Skip to content
Screener

TG Therapeutics TGTX Q3 2025 earnings

Reported November 3, 2025 · Before market open

Revenue$161.7MMiss by $32.1M
EPS$2.43Beat by $2.19
Revenue estimate$193.8M
EPS estimate$0.24

Next report

Nov 2, 2026 (in a month)
Revenue estimate$245.2M
EPS estimate$0.36

Financials

Q3 2025

Income statement

See full
Revenue$161.7M+92.8%
Gross profit$133.6M+79.3%
Operating income$29.4M+136%
Net income$390.9M+9,975%
EPS (diluted)$2.43+12,050%

Balance sheet

See full
Cash & equivalents$74.1M-62.2%
Total debt$253.7M0.0%
Total equity$607.2M+216%
Total assets$1.0B+74.9%

Cash flow

See full
Operating cash flow-$23.2M-89.7%
CapEx$80.0K+233%
Free cash flow-$23.2M-90.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$5.73B+58.3%
Enterprise value$5.91B+60.7%
P/E12.8×—
P/S10.8×-2.9×

Profitability

See full
Gross margin85.3%-3.0pp
Operating margin19.3%—
Net margin84.1%—

Returns & leverage

See full
Return on equity112%—
Debt / equity0.4×-0.9×
Current ratio3.8×-0.8×

FAQ

When did TG Therapeutics report Q3 2025 earnings?
TG Therapeutics (TGTX) reported Q3 2025 earnings on November 3, 2025 before market open.
What were TG Therapeutics's Q3 2025 revenue and EPS?
TG Therapeutics reported revenue of $161.7M and eps of $2.43 for Q3 2025.
Did TG Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $193.8M by $32.1M. EPS beat the consensus estimate of $0.24 by $2.19.
How did TG Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 92.8% from $83.9M a year earlier and eps grew 12050.0% from $0.02.
Where can I find TG Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001437749-25-032658) and the 10-Q periodic report (0001437749-25-033363) directly on SEC EDGAR. The filing index links above go to sec.gov.